Decades Later, Addiction Treatment Still Lags

In 1981, a young chemist began synthesizing buprenorphine in India, a critical medicine for severe pain and addiction. By 1994, after clinical trials, it was approved for treating drug addiction in India. This medicine offers a chance for individuals to cease abusing illicit drugs, curbing the spread of HIV and hepatitis C.

However, societal perception has hindered progress, often criminalizing addiction instead of treating it as a mental health issue. This delay has exacerbated the epidemic, leaving many without accessible treatment. Despite awareness campaigns like the Nasha Mukt Bharat Abhiyaan, reaching millions needing help, the availability of nearby clinics and effective medication remains a significant challenge.

Statistics reveal about 77 lakh Indians require clinical help for opioids, and 5.7 crore drink at harmful levels, with scarce treatment access. The government's three-year plan to triple de-addiction centers to 1,751 by 2029 is a welcomed initiative. Comprehensive public funding and collaboration between government and private sectors are essential for a scalable solution, mirroring past successes in TB treatment.

While India now manufactures buprenorphine and other addiction treatments, too few patients receive them. Urgent government support is needed to scale up holistic addiction treatment with the same priority given during the COVID-19 pandemic.